Oncology Pharma Meeting Towards Future Developments


SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2021 / Oncology Pharma Inc. (OTC PINK: ONPH) Oncology Pharma, Inc. (“The Company”) hosted a meeting with the Board of Directors, officers and members of the Scientific Advisory Board as well as legal counsel, who shared updates. update on the progress in the development of licensed products. This marked a progress towards the pursuit of its main objective of the co-development plan to bring to market new formulations of pharmaceutical drugs with a targeted approach that aims to reduce overall costs and minimize the time and duration of production. commercialization.

During the meeting, Boards of Directors were briefed and discussed the benefits of pursuing specific technologies, such as the Connect2Med trial program with Ribeira Solutions as well as pediatric and orphan drug designations and possible strategies. to pursue for a company of its size. Among these goals is the dactinomycin nanoemulsion. The Company and its partners are currently in the process of creating and testing targeted formulations for inclusion in studies that will undergo extensive testing.

Oncology Pharma developed the framework and is conducting preliminary and initial non-clinical feasibility studies; and is creating data that focuses on the use of its dactinomycin nanoemulsion drug product for the treatment of pediatric cancers. Dactinomycin has been shown to be effective in destroying cancer cells. The use of the nanoemulsion for the targeted delivery system should allow the delivery of a safe dose of the drug over time, so that it can be delivered safely. The Company predicts that as the data is created there will be more developments and opportunities to pursue. With the first indications confirming the initial hypotheses, the work so far has been encouraging and is proceeding as planned.


ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the “Company”) is currently engaged in the research and development of therapeutics for oncology and is proud to have a world-class advisory board that keeps the Company at the forefront of technology development. cancer research, biotechnology and health care.


Some of the matters discussed in this announcement contain forward-looking statements that involve material risks and uncertainties in the affairs of the Company that may cause actual results to differ materially from those anticipated by the statements made here. These risks and uncertainties include risks associated with licensing agreements and joint ventures, including the need to negotiate definitive agreements for the relationships; possible failure to realize the expected benefits of the business relationship; and the costs of financing these business relationships. Other risks and uncertainties relating to the Company include, among others, the current negative operating cash flows and the need for additional financing to finance our operating plan; the terms of any additional funding, which can be very dilutive and may include onerous terms; unanticipated operating costs and deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect greater market acceptance; unfavorable economic conditions; the unfavorable results of any legal proceedings; the volatility of our operating results and financial condition; failure to attract or retain qualified management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to eventually license other patents and patent applications necessary for product development; the Company’s ability to implement its long-term business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and / or distribution partner and with any strategic or joint venture partner; the impact of competition; obtaining and maintaining all necessary regulatory approvals applicable to the applications of the Company’s technology; growth management; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the financial condition of the Company.


For more information, please contact Oncology Pharma at:

Sansome Street, Suite 3500
San Francisco, CA 94104
Telephone: 415-869-1038
Fax: 415-946-8801
website: www.oncologie-pharma.com
email: [email protected]

THE SOURCE: Oncology Pharma inc.

See the source version on accesswire.com:


Comments are closed.